22 resultados para Imunoglobulinas IgM e IgA
Resumo:
Os autores apresentam o caso clínico de uma criança de 18 meses, sexo masculino, raça branca,internada na Unidade de Nefrologia com o diagnóstico de síndroma nefrótico - crise inaugural. Atendendo à idade, aos parâmetros bioquímicos e estudo imunológico negativo, admite-se síndroma nefrótico de lesões mínimas e inicia corticoterapia na dose 60mg/m2/dia. Porqua às seis semanas mantinha edema refractário e comportava-se como corticorresistente, efectuou-se biópsia renal que revelou glomerunefrite membranosa com profileração de crescentes depósitos de IgG, IgA, IgM, C1, C3, C4, C1q, a favor da doença imunológica de base e sugestiva de nefropatia lúpica. O protocolo terapêutico foi revisto e iniciou terapêutica de seis ciclos mensais de ciclofosfamida endovenosa. A resposta clínica laboratorial foi favorável a partir do quarto ciclo e está em remissão após os seis ciclos efectuados e seguimento em ambulatório de 14 meses.
Resumo:
clinical presentation is self limited. It is classified into five groups (genogroups I through V). There are numerous reports of neurologic complications, namely afebrile seizures, but only two reports of associated encephalopathy. Case Report: A 12 month old girl with previous history of a pneumonia treated with amoxicillin-clavulanic acid and clarythromycin, presented in our emergency department with strabismus, ataxia for 3 days, later associated with vomiting and diarrhea. On admission she had ataxia and an episode of strabismus, but her later neurologic exam was normal. Laboratory data revealed: 10,9 g/dL hemoglobin, 11.200/μL leukocytes, 29,1% neutrophils and 65,2% lymphocytes, 488.000/μL platelets and negative CRP. The brain MRI showed middle ear, maxillary sinus and ethmoidal opacification, with no other abnormalities. During the first day of admission she had a tonic (?) seizure for 20 minutes. CSF analysis showed 5,6 cells/μL, 100% lymphocytes, 80 mg/dL glucose and 154,1 mg/dL protein. The EEG revealed short duration paroxystic activity located to the vertex. She was treated with acyclovir, ciprofloxacin, cefthriaxone and phenytoin. Her symptoms resolved by the third day of admission. Blood samples were tested for numerous pathogens, including serology for Borrelia, which was positive for IgG but negative for IgM. Fecal sample analysis revealed positive PCR for norovirus, although it was negative in CSF samples. IL-6 was measured in the CSF and was negative (5,8 pg/mL). She had a history of recurrent otitis media and pernieal candidiasis, which led to a detailed immune function study, which showed Immunology tests revealed diminished IgA (< 0,244 g/L) and absent antibody response to vaccinations. Since she was only 13 months old when she was tested, only follow up will determine the relevance of these values. Follow up at two years of age showed no delays and a normal development. Conclusion: Norovirus encephalitis is a rare entity, although gastrointestinal infection with this agent is relatively common. Here we present a case of a probable norovirus associated encephalopathy, although PCR for norovirus was negative in CSF samples and there was no CSF cytokine increase. It was not associated with adverse neurologic outcome and so far her development is normal, unlike the evolution described in previous case reports.
Resumo:
Introduction. IgA nephropathy is the dominant primary glomerular disease found throughout the majority of the world’s developed countries. Accurately identifying patients who are at risk of progressive disease is challenging. We aimed to characterise clinical and histological features that predict poor prognosis in adults. Patients and Methods. We performed a single-centre retrospective observational study of biopsy-proven IgA nephropathy. The primary outcome was renal survival and death from any cause, and the secondary outcome was proteinuria remission. Results. Data from 49 cases were available for analysis with a median follow-up of 4 years. There were no deaths. Univariable analyses identified acute renal failure, low estimated glomerular filtration rate for ≥3 months (low eGFR), arterial hypertension, baseline proteinuria, glomerular sclerosis >50% and interstitial fibrosis >50% as poor prognostic markers. Low eGFR persisted significant by multivariable model that used only clinical parameters. Multivariable models with histopathologic parameters observed that tubular atrophy/interstitial fibrosis >50% was independently associated with the primary outcome. Proteinuria remission throughout follow-up had no prognostic value in our revision. Conclusions. Two independent predictors of poor renal survival at time of biopsy were found: low eGFR and tubular atrophy/interstitial fibrosis >50%.
Resumo:
We report the case of a boy with an encephalopathy associated with extrapyramidal and psychiatric symptoms and anti-N-methyl-D-aspartate receptor antibodies. He had positive serum antithyroid antibodies, IgM antibodies against Mycoplasma pneumoniae and human herpesvirus 7 polymerase chain reaction in the cerebrospinal fluid. He was successfully treated with rituximab, after steroids, intravenous immunoglobulin and plasma exchange. The pathophysiology of this disorder may be post-infectious and autoimmune.
Resumo:
Dabigatran is a direct thrombin inhibitor used as an alternative to warfarin for long term anticoagulation. Warfarin-related nephropathy is an increasingly recognized entity, but recent evidence suggests that dabigatran can cause a WRN-like syndrome. We describe a case of a biopsy-proven anticoagulant nephropathy related to dabigatran in a patient with IgA nephropathy and propose that, despite the base glomerular disease, acute kidney injury was due to tubular obstruction by red blood cells and heme-associated tubular injury, and through a mechanism involving inhibition of anticoagulation cascade and barrier abnormalities caused by molecular mechanisms.
Resumo:
Na infecção pelo vírus da imunodeficiência humana (VIH) estão descritas alterações cardiovasculares, tanto estruturais como funcionais. Com o objectivo de fazer o rastreio das referidas alterações no propósito de uma intervenção terapêutica precoce, foi efectuada uma avaliação clínica e laboratorial prospectiva em 32 crianças com infecção pelo VIH, com idades compreendidas entre três meses e 13 anos (média = 3.11 +/- 3.51 anos). Em 90% dos doentes identificou-se transmissão perinatal. Vinte e duas crianças (69%) estavam sintomáticas, sendo a sintomatologia moderada em nove e grave em oito. Catorze doentes tinham alterações imunológicas e oito delas apresentavam imunosupressão grave. Vinte e oito crianças (88%)tinham infecção pelo VIH 1 e seis tinham infecção recente pelo Vírus de Ebstein-Barr. Dezanove doentes receberam tratamento com zidovudina e 14 com imunoglobulinas por via endovenosa. Foram detectadas 19 alterações cardiovasculares em 15 doentes (47%), nomeadamente: 11 casos de hipertensão pulmonar por critérios ecocardiográficos, (oito delas tinham infiltrados intersticiais na radiografia do tórax) e quatro casos de disfunção ventricular esquerda que, por isso, iniciaram terapêutica anticongestiva. As restantes anomalias estruturais ou funcionais foram: persistência de canal arterial; hipertrofia do septo interventricular; prolapso da válvula mitral e derrame pericárdico cada uma delas em um caso. No electrocardiograma de superfície quatro crianças apresentaram critérios de hipertrofia ventricular direita, uma tinha hipertrofia ventricular esquerda e duas tinham alterações inespecíficas de repolarização ventricular. Em 14 doentes (44%) verificou-se no ECG de 24 horas taquicardia sinusal com uma frequência cardíaca média superior ao percentil 95. As anomalias cardiovasculares foram mais frequentes nas crianças com estadios mais avançados de doença. Conclusões: As anomalias cardiovasculares são frequentes em crianças com infecção pelo VIH em estadios avançados; a hipertensão pulmonar é a anomalia cardiovascular mais frequentemente detectada e está associada a patologia respiratória crónica ou recorrente; o acompanhamento cardiológico está indicado nas crianças com infecção pelo vírus da imunodeficiência humana.
Resumo:
Herein we have described the case of a male renal transplant recipient who developed drug fever apparently related to sirolimus. He had been stable under an immunosuppressive regimen of tacrolimus and mycophenolate mofetil, but developed acute cellular rejection at 5 years after transplantation due to noncompliance. Renal biopsy showed marked interstitial fibrosis, and immunosuppression was switched from mycophenolate to sirolimus, maintaining low tacrolimus levels. One month later he was admitted to our hospital for investigation of intermittently high fever, fatigue, myalgias, and diarrhea. Physical examination was unremarkable and drug levels were not increased. Lactic dehydrogenase and C-reactive protein were increased. The blood cell count and chest radiographic findings were normal. After extensive cultures, he was started on broad-spectrum antibiotics. Inflammatory markers and fever worsened, but diarrhea resolved. All serologic and imaging tests excluded infection, immune-mediated diseases, and malignancy. After 12 days antibiotics were stopped as no clinical improvement was achieved. Drug fever was suspected; sirolimus was replaced by mycophenolate mofetil. Fever and other symptoms disappeared after 24 hours; inflammatory markers normalized in a few days. After 1 month the patient was in good health with stable renal function. Although infrequent, the recognition of drug fever as a potential side effect of sirolimus may avoid unnecessary invasive diagnostic procedures. Nevertheless, exclusion of other common causes of fever is essential.
Resumo:
Introduction: Toxoplasmosis is caused by Toxoplasma gondii and may be acquired from food or water contaminated with cat feces or by vertical transmission. Severe fetal complications can overcome during pregnancy. There are also rare case-reports of congenital toxoplasmosis from previously immunized pregnant women; usually these women being had prior retinal toxoplasmic lesions. Immunosuppresion is one of the risk factors which accounts for some of these cases. Case report: 30 year-old pregnant woman, OI 2002, brazilian, previously healthy, admitted in Ophtalmology Department because of sudden left eye amaurosis in June, 2010. The fundoscopy revealed retinal scars suggesting previous infections; she was treated with corticoids and spiramycin for ocular toxoplasmosis reactivation. Previous serum analysis (2008) showed immunity to T. Gondii, but in July the IgM was negative and high levels of specific IgG were found (1227UI/mL). The serologic findings were later confirmed by a more accurate laboratory technique which found the IgM to be also positive. An amniocentesis was performed and it was negative for fetal transmission. Clinical and ultrasound follow-up throughout the rest of the gestational period was normal; daily spiramycin intake was maintained. An uneventful term delivery was performed. Neither the newborn’s serum analysis nor the histopathological study of the placenta were positive for congenital infection. Conclusion: Toxoplasmosis reactivation in pregnant women without immunosuppression is rare but is more likely to occur if previous post-infectious retinal scars are present. T. gondii infection is endemic in Brazil, so the geographical origin is important. If risk factors are present, fundoscopy should be performed every three months during pregnancy and one should always be aware of any visual symptoms. If you suspect reactivation, start medical prophylaxis for fetal transmission, perform amniocentesis and regular ultrasound follow-up.
Resumo:
Introdução: A narcolepsia é uma doença do sono REM com desregulação do ciclo de sono-vigília, consequente sonolência diurna e eventual associação a alucinações hipnagógicas, paralisia do sono e cataplexia. A sua prevalência é de 0,05 a 0,02% no adulto mas desconhecida na idade pediátrica. Caso clínico: Criança de seis anos, previamente saudável com sonolência excessiva até 18 horas/dia e discinésia oromandibular, desequilíbrio na marcha e movimentos coreiformes dos membros superiores. Duas semanas antes realizara vacinação para a gripe pandémica. Registou-se ainda hiperfagia diurna e nocturna durante cinco dias com resolução espontânea, episódios de cataplexia perante riso e alterações emocionais e tremor da cabeça e dos membros superiores com melhoria clínica progressiva após oito dias. Realizou RMN-CE e EEG sem alterações. O exame líquido céfalo-raquidiano e PCR para painel de vírus herpes, Mycoplasma pneumoniae e enterovírus negativas. Nesta fase realizou polissonografia com teste de latências múltiplas do sono (TLMS) sem alterações. Exame cultural do exsudado faríngeo, TASO e anticorpo AntiDnase B negativos. Da exaustiva investigação que realizou apresentava serologias ELISA e WB compatíveis com infecção por Borrelia burdorferi, pelo que cumpriu ceftriaxone 14 dias. Serologias para influenza A mostraram IgM 39 UA/mL com IgG 194 UA/mL com segunda amostra com IgM 43 UA/mL e IgG 162 UA/mL (VR IgM<20;IgG<20). O estudo da autoimunidade revelou ANA 1/320, anticorpos anticardiolipina e antinucleares extraíveis negativos. Restantes autoanticorpos e doseamento de complemento normal. Anticorpos Anti-NMDA e VKCG negativos. Doseamento de hipocretina muito diminuído com HLA DR2 e DQB1*0602 presentes. A polissonografia com TLMS, sete meses após a primeira, confirmou sonolência excessiva com quatro inícios do sono REM sugestivos de narcolepsia. Faz terapêutica com metilfenidato, a sonolência diurna diminuiu e cumpre o seu horário escolar sem limitações. Comentários: O diagnóstico de narcolepsia foi sugerido pela clínica e confirmado pelo teste de latências múltiplas. O valor de hipocretina diminuído pode sugerir uma etiologia autoimune. Uma infecção como a borreliose ou a vacinação prévia para H1N1, responsabilizada por outros casos de narcolepsia podem ter sido desencadeantes de uma alteração imunitária responsável pela doença, nesta criança com a susceptibilidade HLA DR2 e DBQ1*0602.
Resumo:
Renal transplant in highly sensitised patients is associated with increased morbidity. The aim of this retrospective study was to evaluate the clinical evolution of 30 highly sensitised deceased donor kidney transplants and the influence of different timing of B cell directed treatment and its importance in the outcome of these patients. All recipients had negative complement dependent lymphocytotoxicity cytotoxic T cell crossmatch and no identified anti human leucocyte antigen class I donor specific antibodies. T cell flow crossmatch was performed within 24h of transplantation with serum obtained pretransplant (historic, recent or baseline). Posttransplant flow crossmatch were performed prospectively starting on the 3rd posttransplantation day. The immunosuppressive regime included thymoglobulin, tacrolimus, mycofenolate mofetil and steroids. Positive flow crossmatch occurred in 20/29 patients by the 3rd posttransplantation day, and in 17/27 patients after the 3rd posttransplantation day. All patients were started on intravenous immunoglobulin before transplantation: in nine patients (group A) at 400mg/kg/day for five days; in the remaining 21 patients (group B), as a continued infusion of 2g/kg during 48h. In group A, Rituximab was added only in the presence of antibody mediated rejection; in group B, introduced on the 3rd posttransplantation day whenever a positive flow crossmatch (with serum obtained pre or posttransplant) was reported. Antibody mediated rejection was observed in 44.4% of patients in group A, and 19% of those in group B. Mean follow-up was 12.2±5.5 months. Overall allograft survival was 76.6%, 81% in group B, and 66.6% in group A. At last follow up, mean serum creatinine was 1.3±0.6 mg/dl. Renal transplantation with pretransplant positive flow crossmatch is highly associated with antibody mediated rejection, despite introduction of intravenous immunoglobulin pretransplantation. However high dose intravenous immunoglobulin for 48h plus Rituximab by the 3rd posttransplantation day reduce the incidence of antibody mediated rejection by more than 50% and allowed for allograft survival of 81% at one year, with an excellent renal function.
Resumo:
Introducão: A toxoplasmose congénita é evitável: rastreio universal, serologias repetidas na gravidez de mulheres com serologia negativa e início precoce de terapêutica aquando de seroconversão durante a gravidez são medidas de grande importância para a prevenção da infecção congénita. Apesar disso não é consensual o rastreio universal na gravidez e muitos países desenvolvidos não o fazem. Em Portugal é feito o rastreio sistemático com 3 determinações serológicas nas mulheres negativas. Contudo não é conhecido o número de casos de infecção congénita. Em Janeiro de 2006 teve início o Registo Nacional da Infecção Congénita por Toxoplasma gondii com o objectivo de conhecer o número de casos de infecção congénita em Portugal. Materiais e Métodos: Desenho: Estudo de vigilância epidemiológica nacional. A metodologia do registo foi explicada em estudos anteriores e os critérios de inclusão bem definidos. Resultados: Foram notificados 30 casos nos 2 anos. Houve 12 seroconversões durante a gravidez; em 10 casos havia positividade de IgM e IgG ou IgM sem IgG; 7 tinham serologia compatível com infecção antiga e num caso não foram referidos os resultados das serologias. Em 13 grávidas foi realizada amniocentese, em 8 foi determinada a PCR no LA – negativa em todas; num caso foi determinada a IgM no LA também negativa e em 4 caso foi realizada inoculação de LA no murganho – resultados todos negativos. Apenas 6 casos foram validados: dois eram sintomáticos e ambos tinham PCR e IgM positiva. Os restantes 4 casos eram assintomáticos: dois tinham, PCR positiva e IgM negativa e outros dois tinham PCR negativa/IgM negativa. No total foram realizadas PCR no sangue em 16 RN, 4 dos quais tiveram resultado positivo; IgM em 27, dos quais 4 tiveram resultado positivo; não foi referido nenhuma inoculação no murganho. Não é conhecido o estudo evolutivo de nenhuma destas crianças. Comentários: A incidência de infecção congénita encontrada no estudo foi de 2,9/100 000NV. De acordo com os valores encontrados pelo IRJ seria de esperar uma incidência de 12/100 000 NV. O baixo número de casos deve-se provavelmente a sub notificação e impede tirar qualquer conclusão.
Resumo:
INTRODUCTION: ABO-incompatible liver transplantation (ABOi LT) is considered to be a rescue option in emergency transplantation. Herein, we have reported our experience with ABOi LT including long-term survival and major complications in these situations. PATIENT AND METHODS: ABOi LT was performed in cases of severe hepatic failure with imminent death. The standard immunosuppression consisted of basiliximab, corticosteroids, tacrolimus, and mycophenolate mofetil. Pretransplantation patients with anti-ABO titers above 16 underwent plasmapheresis. If the titer was above 128, intravenous immunoglobulin (IVIG) was added at the end of plasmapheresis. The therapeutic approach was based on the clinical situation, hepatic function, and titer evolution. A rapid increase in titer required five consecutive plasmapheresis sessions followed by administration of IVIG, and at the end of the fifth session, rituximab. RESULTS: From January 2009 to July 2012, 10 patients, including 4 men and 6 women of mean age 47.8 years (range, 29 to 64 years), underwent ABOi LT. At a mean follow-up of 19.6 months (range, 2 days to 39 months), 5 patients are alive including 4 with their original grafts. One patient was retransplanted at 9 months. Major complications were infections, which were responsible for 3 deaths due to multiorgan septic failure (2 during the first month); rejection episodes (4 biopsy-proven of humoral rejections in 3 patients and 1 cellular rejection) and biliary. CONCLUSION: The use of ABOi LT as a life-saving procedure is justifiable in emergencies when no other donor is available. With careful recipient selection close monitoring of hemagglutinins and specific immunosuppression we have obtained acceptable outcomes.
Resumo:
O défice da proteína do gene activador da recombinase resulta numa incapacidade de formação de antigénios por deficiente recombinação, o que se traduz por uma ausência quase completa de marcadores T e B nas populações linfocitárias com aumento relativo de marcadores NK. Clínicamente esta alteração revela-se como uma Imunodeficiência Combinada Severa de particular gravidade. Sem a realização precoce de transplante medular de um dador compatível a mortalidade é de 100% aos 2 anos de idade. Descrevemos um caso de um lactente, filho de pais consaguíneos, internado no nosso hospital, aos 6 meses de vida por síndrome hemolítico-urémico na sequência de pneumonia pneumocócica com derrame. Após terapia inyensiva verifica-se recuperação total da função renal mas desnutrição importante. A evolução posterior é caracterizada por infecções recorrentes, escaras cutâneas e agravamento da desnutrição. Laboratorialmente apresenta leucopénia e linfopénia persistente com valores muito baixos das imunoglobulinas séricas e ausência quase total das populações B. O estudo genérico revela existência de um défice proteico do gene activador da recombinase (RAG)2. Foi possível a exclusão da mesma patologia num irmão, nascido posteriormente, por análise do sangue do cordão. Julgamos tratar-se do primeiro caso confirmado desta situação diagnosticada num doente em Portugal.
Resumo:
A trombocitopenia é a alteração hemostática mais frequente na gravidez, sendo mais comum no IIIº trimestre ou intra parto. É um sinal de uma anomalia coincidente ou provocada pela gravidez com diferentes graus de gravidade. Daí a necessidade de um diagnóstico correcto destas situações. A propósito de vários casos de trombocitopenia ocorridos no Serviço de Medicina Materno-Fetal da MAC e após revisão bibliográfica, os autores propuseram a elaboração de um protocolo de diagnóstico e de terapêutica destas situações na gravidez.
Resumo:
BACKGROUND: This study was designed to investigate, for the first time, the short-term molecular evolution of the HIV-2 C2, V3 and C3 envelope regions and its association with the immune response. Clonal sequences of the env C2V3C3 region were obtained from a cohort of eighteen HIV-2 chronically infected patients followed prospectively during 2-4 years. Genetic diversity, divergence, positive selection and glycosylation in the C2V3C3 region were analysed as a function of the number of CD4+ T cells and the anti-C2V3C3 IgG and IgA antibody reactivity RESULTS: The mean intra-host nucleotide diversity was 2.1% (SD, 1.1%), increasing along the course of infection in most patients. Diversity at the amino acid level was significantly lower for the V3 region and higher for the C2 region. The average divergence rate was 0.014 substitutions/site/year, which is similar to that reported in chronic HIV-1 infection. The number and position of positively selected sites was highly variable, except for codons 267 and 270 in C2 that were under strong and persistent positive selection in most patients. N-glycosylation sites located in C2 and V3 were conserved in all patients along the course of infection. Intra-host variation of C2V3C3-specific IgG response over time was inversely associated with the variation in nucleotide and amino acid diversity of the C2V3C3 region. Variation of the C2V3C3-specific IgA response was inversely associated with variation in the number of N-glycosylation sites. CONCLUSION: The evolutionary dynamics of HIV-2 envelope during chronic aviremic infection is similar to HIV-1 implying that the virus should be actively replicating in cellular compartments. Convergent evolution of N-glycosylation in C2 and V3, and the limited diversification of V3, indicates that there are important functional constraints to the potential diversity of the HIV-2 envelope. C2V3C3-specific IgG antibodies are effective at reducing viral population size limiting the number of virus escape mutants. The C3 region seems to be a target for IgA antibodies and increasing N-linked glycosylation may prevent HIV-2 envelope recognition by these antibodies. Our results provide new insights into the biology of HIV-2 and its relation with the human host and may have important implications for vaccine design.